Efficacy and Safety of Tocilizumab Treatment in Tunisian Critically Ill COVID-19 Patients
Background. COVID-19 is the major cause of serious acute respiratory complications, leading to strong perturbation of cytokine release and high levels of interleukin-6. In this work, we assessed the efficacy and safety of Tocilizumab in Tunisian patients with severe COVID-19. Materials and Methods....
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2024/2585821 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849408787522256896 |
|---|---|
| author | Khadija Bahrini Hamza Ben Cheikh Larbi Mouna Ben Azaiez Nejla Stambouli Mohamed Zakraoui Sana Boughariou Mohamed Ali Yousfi Iheb Labbene Mayssa Daiki Hédi Gharsallah Chihebeddine Romdhani Mustapha Ferjani |
| author_facet | Khadija Bahrini Hamza Ben Cheikh Larbi Mouna Ben Azaiez Nejla Stambouli Mohamed Zakraoui Sana Boughariou Mohamed Ali Yousfi Iheb Labbene Mayssa Daiki Hédi Gharsallah Chihebeddine Romdhani Mustapha Ferjani |
| author_sort | Khadija Bahrini |
| collection | DOAJ |
| description | Background. COVID-19 is the major cause of serious acute respiratory complications, leading to strong perturbation of cytokine release and high levels of interleukin-6. In this work, we assessed the efficacy and safety of Tocilizumab in Tunisian patients with severe COVID-19. Materials and Methods. We enrolled in this retrospective study 255 critically ill patients in the intensive care unit of the military hospital of Tunis. These patients were categorized into a standard group (n = 148) and a Tocilizumab group (n = 107). Medical records were gathered and analyzed between September, 2020 and September, 2021. Results. No significant difference was detected in clinical and biological parameters at admission between the two studied groups. Interestingly, we revealed here a significant improvement in respiratory parameters as well as biological findings such as hemoglobin (p=0.001), platelets (p=0.005), CRP (p=0.0001), fibrinogen (p=0.0001), and creatinine (p=0.002). Regarding the Simplified Acute Physiology Score II and 28-day mortality, we showed a significant decrease of these two parameters following 48 hr of drug administration (p=0.0001, respectively). No significant difference between the two groups regarding complications except the renal failure and the need for renal replacement therapy, which are higher in the standard group as compared to patients treated with Tocilizumab (p=0.02; p=0.0001, respectively). Conclusions. Treatment with TCZ seems to be safe and effective in reducing the mortality rate in severe COVID-19 patients. |
| format | Article |
| id | doaj-art-7a45b559edb0482cb7fd9596e7c7d70d |
| institution | Kabale University |
| issn | 2314-7156 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-7a45b559edb0482cb7fd9596e7c7d70d2025-08-20T03:35:41ZengWileyJournal of Immunology Research2314-71562024-01-01202410.1155/2024/2585821Efficacy and Safety of Tocilizumab Treatment in Tunisian Critically Ill COVID-19 PatientsKhadija Bahrini0Hamza Ben Cheikh Larbi1Mouna Ben Azaiez2Nejla Stambouli3Mohamed Zakraoui4Sana Boughariou5Mohamed Ali Yousfi6Iheb Labbene7Mayssa Daiki8Hédi Gharsallah9Chihebeddine Romdhani10Mustapha Ferjani11Research Unit UR17DN05Department of Anesthesiology and Intensive CareDepartment of ImmunologyResearch Unit UR17DN05Department of Anesthesiology and Intensive CareDepartment of Anesthesiology and Intensive CareDepartment of PharmacyUniversity Tunis El ManarDepartment of Anesthesiology and Intensive CareResearch Unit UR17DN05University Tunis El ManarUniversity Tunis El ManarBackground. COVID-19 is the major cause of serious acute respiratory complications, leading to strong perturbation of cytokine release and high levels of interleukin-6. In this work, we assessed the efficacy and safety of Tocilizumab in Tunisian patients with severe COVID-19. Materials and Methods. We enrolled in this retrospective study 255 critically ill patients in the intensive care unit of the military hospital of Tunis. These patients were categorized into a standard group (n = 148) and a Tocilizumab group (n = 107). Medical records were gathered and analyzed between September, 2020 and September, 2021. Results. No significant difference was detected in clinical and biological parameters at admission between the two studied groups. Interestingly, we revealed here a significant improvement in respiratory parameters as well as biological findings such as hemoglobin (p=0.001), platelets (p=0.005), CRP (p=0.0001), fibrinogen (p=0.0001), and creatinine (p=0.002). Regarding the Simplified Acute Physiology Score II and 28-day mortality, we showed a significant decrease of these two parameters following 48 hr of drug administration (p=0.0001, respectively). No significant difference between the two groups regarding complications except the renal failure and the need for renal replacement therapy, which are higher in the standard group as compared to patients treated with Tocilizumab (p=0.02; p=0.0001, respectively). Conclusions. Treatment with TCZ seems to be safe and effective in reducing the mortality rate in severe COVID-19 patients.http://dx.doi.org/10.1155/2024/2585821 |
| spellingShingle | Khadija Bahrini Hamza Ben Cheikh Larbi Mouna Ben Azaiez Nejla Stambouli Mohamed Zakraoui Sana Boughariou Mohamed Ali Yousfi Iheb Labbene Mayssa Daiki Hédi Gharsallah Chihebeddine Romdhani Mustapha Ferjani Efficacy and Safety of Tocilizumab Treatment in Tunisian Critically Ill COVID-19 Patients Journal of Immunology Research |
| title | Efficacy and Safety of Tocilizumab Treatment in Tunisian Critically Ill COVID-19 Patients |
| title_full | Efficacy and Safety of Tocilizumab Treatment in Tunisian Critically Ill COVID-19 Patients |
| title_fullStr | Efficacy and Safety of Tocilizumab Treatment in Tunisian Critically Ill COVID-19 Patients |
| title_full_unstemmed | Efficacy and Safety of Tocilizumab Treatment in Tunisian Critically Ill COVID-19 Patients |
| title_short | Efficacy and Safety of Tocilizumab Treatment in Tunisian Critically Ill COVID-19 Patients |
| title_sort | efficacy and safety of tocilizumab treatment in tunisian critically ill covid 19 patients |
| url | http://dx.doi.org/10.1155/2024/2585821 |
| work_keys_str_mv | AT khadijabahrini efficacyandsafetyoftocilizumabtreatmentintunisiancriticallyillcovid19patients AT hamzabencheikhlarbi efficacyandsafetyoftocilizumabtreatmentintunisiancriticallyillcovid19patients AT mounabenazaiez efficacyandsafetyoftocilizumabtreatmentintunisiancriticallyillcovid19patients AT nejlastambouli efficacyandsafetyoftocilizumabtreatmentintunisiancriticallyillcovid19patients AT mohamedzakraoui efficacyandsafetyoftocilizumabtreatmentintunisiancriticallyillcovid19patients AT sanaboughariou efficacyandsafetyoftocilizumabtreatmentintunisiancriticallyillcovid19patients AT mohamedaliyousfi efficacyandsafetyoftocilizumabtreatmentintunisiancriticallyillcovid19patients AT iheblabbene efficacyandsafetyoftocilizumabtreatmentintunisiancriticallyillcovid19patients AT mayssadaiki efficacyandsafetyoftocilizumabtreatmentintunisiancriticallyillcovid19patients AT hedigharsallah efficacyandsafetyoftocilizumabtreatmentintunisiancriticallyillcovid19patients AT chihebeddineromdhani efficacyandsafetyoftocilizumabtreatmentintunisiancriticallyillcovid19patients AT mustaphaferjani efficacyandsafetyoftocilizumabtreatmentintunisiancriticallyillcovid19patients |